Welcome to the e-CCO Library!

P607: HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Doherty, J.(1)*;Ryan, A.(2);Quinn, E.(2);Dolan, J.(2);Corcoran, R.(3);O' Hara, F.(4);Bailey, Y.(4);McNamara, D.(4);Doherty, G.(5);Kevans, D.(3);
Created: Friday, 14 July 2023, 11:05 AM
P607: Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ordas I.*1, Domenech E.2, Aguas M.3, Fernandez-Bañares F.4, García S.5, Peñalva M.6, Muñoz C.7, García-Sánchez V.8, Llaό J.9, Jiménez C.E.10, Merino O.11, Gomollόn F.12, Piqueras M.13, Vera M.14, Márquez L.15, De Castro M.16, Gutiérrez A.17, Cabriada J.L.18, Alcaide N.19, Calvet X.20, Montoro M.A.21, Arias L.22, Panés J.1, Esteve M.4

Created: Wednesday, 20 February 2019, 10:36 AM
P607: The Faroese IBD Study: Update on incidence from 2015-2020 and prevalence from 1960-2020
Year: 2021
Source: ECCO'21 Virtual
Authors: Nielsen, K.R.(1);Midjord, J.(1);Hammer, T.(2);Lophaven, S.(3);Burisch, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P608 Endoscopic treatment of enterocutaneous fistulas in Crohn’s disease patient
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Yzet, J.P. Le Mouel, S. Hakim, F. Brazier, M. Fumery

Created: Thursday, 30 January 2020, 10:12 AM
P608: Crohn’s disease patients with high baseline symptoms achieve clinical remission more rapidly with Budesonide than with Mesalazine
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Kunz*1, R. Hofmann1

Created: Friday, 22 February 2019, 9:41 AM
P608: Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
Year: 2021
Source: ECCO'21 Virtual
Authors: Zabana Abdo, Y.(1,2);Marín-Jiménez, I.(3);Rodríguez-Lago, I.(4);Ramírez Esteso, F.(5);Meijilde, S.(6);Ramos, L.(7);Gomollón, F.(2,8);Muñoz, F.(9);Suris, G.(10);Ortiz de Zárate, J.(11);Huguet, J.M.(12);Llaó, J.(13);García-Sepulcre, M.(14);Sierra, M.(15);Durà, M.(16);Estrecha, S.(17);Fuentes Coronel, A.(18);Hinojosa, E.(19);Olivan, L.(20);Iglesias, E.(21);Gutiérrez, A.(2,22);Varela, P.(23);Rull, N.(24);Gilabert, P.(25);Hernández-Camba, A.(26);Brotons, A.(27);Ginard, D.(28);Sesé, E.(29);Carpio, D.(30);Aceituno, M.(1,2);Cabriada, J.L.(4);González-Lama, Y.(31);Jiménez, L.(32);Chaparro, M.(2,33);López-San Román, A.(34);Alba, C.(35);Plaza-Santos, R.(36);Piqueras, M.(37);Domènech, E.(2,38);Esteve, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P608: IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with inflammatory bowel disease unable to take oral iron: A randomised controlled trial vs. ferric carboxymaltose
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Strauss*, N. Dahl, J. Jiang, K. Bernard, R. Kaper, J. Krop

Created: Thursday, 21 February 2019, 9:14 AM
P608: New anti-migration extractible metal stents for Crohn's disease strictures: a nationwide GETAID-SFED cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Attar A.*1, Branche J.2, Coron E.3, Privat J.4, Caillo L.5, Chevaux J.-B.6, Vuitton L.7, Amiot A.8, Belkhodja H.9, Buisson A.10, Dray X.11, Jerber L.12, Ponchon T.13, Bouhnik Y.1, Peyrin-Biroulet L.6

Created: Wednesday, 20 February 2019, 10:36 AM
P608: Systematic review: The impact and importance of body composition in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Ding, N.(1,2);Tassone, D.(1);Al Bakir, I.(2);Wu, K.(1);Connell, W.(1);Thompson, A.(1);Malietzis, G.(3);Lung, P.(2);Singh, S.(4);Choi, C.H.(2);Gabe, S.(2);Jenkins, J.(3);Hart, A.(2);
Created: Friday, 11 February 2022, 3:56 PM
P608: Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Attauabi, M.(1,2)*;Dahl, E.K.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Levy1, H. Matz2, N. Maharshak3, A. Waizbard4

Created: Thursday, 30 January 2020, 10:12 AM
P609: A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Little R., Taylor K., Friedman A., Headon B., Gibson P., Sparrow M., Ward M.

Created: Wednesday, 20 February 2019, 10:36 AM
P609: Handsewn anastomosis after ileo-colic resection for Crohn’s disease: a lost art?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Gouvea Monteiro de Camargo1, S. Brandstetter1, A. Aiello2, L. Stocchi1, T. Hull1, I. Lavery1, J. M. Church1, S. R. Steele1, M. Valente1, S. Holubar*1

Created: Friday, 22 February 2019, 9:41 AM
P609: Impact of accessibility of medical care and socioeconomic class on outcomes of IBD – a nationwide population study
Year: 2021
Source: ECCO'21 Virtual
Authors: Ledder, O.(1);Harel, S.(1);Orlanski-Meyer, E.(1);Yogev, D.(1);Loewenberg Weisband, Y.(2);Greenfeld, S.(3);Kariv, R.(3);Lederman, N.(4);Matz, E.(5);Schwartz, D.(6);Focht, G.(1);Dotan, I.(7);Turner, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P609: Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Colombel, J.F.(1)*;Rubin, D.T.(2);Vermeire, S.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Dignass, A.(5);Regueiro, R.(6);
Created: Friday, 14 July 2023, 11:05 AM
P609: Significant variations in practice in managing mild-Crohn’s disease: results from the 2021 Y-ECCO-ClinCom survey
Year: 2022
Source: ECCO'22
Authors: Dart, R.(1,2);Irving, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P609: Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cañete1,2*, T. Lobatón2, E. Cabré2,3, M. Mañosa2,3, A. Teniente4, A. Clos2, P. Torres2, G. Valldosera2, E. Martínez-Cáceres4, E. Domènech2,3

Created: Thursday, 21 February 2019, 9:14 AM
P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. REES, C. Maher, J. Jones, J. Slater, B. Bates, D. Rattehalli, S. De Silva

Created: Thursday, 30 January 2020, 10:12 AM
P610: Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, Reinisch W.2,3, Wasko-Czopnik D.4, Van Kaem T.5, Desrivot J.6, Vanhoutte F.5, Beetens J.5

Created: Wednesday, 20 February 2019, 10:36 AM
P610: Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions
Year: 2021
Source: ECCO'21 Virtual
Authors: Lo, B.Z.S.(1);Mokrowiecka, A.(2);Mikocka-Walus, A.(3);Bernstein, C.N.(4,5);Trindade, I.A.(6);Burisch, J.(1);Barreiro-de Acosta, M.(7);Ferreira, N.(8);Gearry, R.B.(9);Knowles, S.R.(10);
Created: Wednesday, 2 June 2021, 4:12 PM